UroGen Pharma Ltd. (URGN) has announced the appointment of Chris Degnan as its new Chief Financial Officer, succeeding Don Kim, who is departing the company for new opportunities.
Chris Degnan brings to UroGen substantial experience in the biotech sector, having served as CFO at Galera Therapeutics and Verrica Pharmaceuticals. He possesses comprehensive expertise in areas such as financial strategy, investor relations, SEC reporting, accounting, and compliance.
Earlier in his career, Mr. Degnan held senior roles at Endo International plc. Prior to his tenure at Endo, he spent over a decade with biopharmaceutical giant AstraZeneca plc.
To mark his new role at UroGen, Degnan has been awarded an inducement grant of restricted stock units equivalent to 13,450 ordinary shares, along with a stock option to acquire up to 74,142 ordinary shares of UroGen. The exercise price for this stock option is set at $13.11.